Company Filing History:
1 out of 1,745 
1 out of 33 
1 out of 1 Years Active: 2019
Title: Fabrice Jardin: Innovator in Lymphoma Classification
Introduction
Fabrice Jardin is a notable inventor based in Rouen, France. He has made significant contributions to the field of medical research, particularly in the classification of diffuse large B-cell lymphomas (DLBCLs). His innovative methods have the potential to enhance diagnostic accuracy and treatment strategies for patients suffering from this type of cancer.
Latest Patents
Fabrice Jardin holds a patent for "Methods and kits for classifying diffuse large B-cell lymphomas (DLBCLs) into GCB-DLBCLs or into ABC-DLBCLs." This invention involves a method for classifying a DLBCL by determining the expression level of ten specific genes in a tumor tissue sample. The genes involved in this classification are NEK6, IRF4, IGHM, LMO2, FOXP1, TNFRSF9, BCL6, TNFRSF13B, CCND2, and MYBL1. The method utilizes a Reverse Transcriptase Multiplex Ligation dependent Probe Amplification (RT-MLPA) assay, which is a sophisticated technique for gene expression analysis.
Career Highlights
Throughout his career, Fabrice Jardin has worked with esteemed institutions such as the Institut National de la Santé et de la Recherche Médicale and the Université de Rouen. His work in these organizations has allowed him to collaborate with leading experts in the field of medical research, furthering his contributions to lymphoma classification.
Collaborations
Fabrice Jardin has collaborated with notable colleagues, including Philippe Ruminy and Sylvain Mareschal. These partnerships have played a crucial role in advancing his research and the development of his patented methods.
Conclusion
Fabrice Jardin's innovative work in the classification of diffuse large B-cell lymphomas represents a significant advancement in cancer research. His contributions have the potential to improve patient outcomes through more accurate diagnostics and targeted therapies.